GlassScriptPhysician profile
Dennis K Ledford
NPI 1376528042
$1,186,289.32
in general payments reported to CMS, 2019-2025
31 companies · $190K in 2025
The $190K reported for 2025 was more than what 99% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217K · 2020: $89K · 2021: $121K · 2022: $189K · 2023: $207K · 2024: $173K · 2025: $190K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $452K · Travel and Lodging: $57K · Consulting Fee: $43K · Food and Beverage: $17K · Education: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $452,233.90 |
| Travel and Lodging | $56,801.10 |
| Consulting Fee | $43,387.39 |
| Food and Beverage | $16,764.31 |
| Education | $143.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $364,433.92 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $337,890.53 | 2019-2025 | Nucala |
| Genzyme Corporation | $190,837.21 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $125,821.53 | 2019-2025 | Dupixent |
| Genentech USA, INC. | $71,613.78 | 2019-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $22,208.80 | 2019-2025 | |
| Amgen INC. | $21,799.07 | 2021-2025 | Tezspire |
| Alk-Abello, INC | $16,552.96 | 2019-2020 | |
| Csl Behring | $13,140.96 | 2019-2025 | Andembry |
| Biocryst Pharmaceuticals, INC. | $8,484.44 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $4,571.92 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,862.86 | 2019-2020 | |
| Blueprint Medicines Corporation | $2,092.03 | 2020-2025 | Ayvakit |
| Abbvie INC. | $1,757.10 | 2021-2022 | |
| Shire North American Group INC | $209.27 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $200.41 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $191.14 | 2020-2025 | Takhzyro, Cinryze |
| Adma Biomanufacturing LLC | $128.72 | 2025 | |
| Circassia INC. | $96.74 | 2019 | |
| Lilly USA, LLC | $90.23 | 2024-2025 | Ebglyss |
| Covis Pharma Gmbh | $60.88 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $60.35 | 2019-2021 | |
| Optinose US, INC. | $48.03 | 2019 | |
| Pfizer INC. | $40.38 | 2019-2020 | |
| Octapharma USA, INC. | $32.25 | 2019 | |
| Grifols USA, LLC | $18.88 | 2020 | |
| Insmed, INC. | $17.38 | 2025 | |
| Pharming Healthcare, INC. | $14.76 | 2019 | |
| Kaleo, INC. | $12.79 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Ledford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.